AXSOME THERAPEUTICS ($AXSM) posted quarterly earnings results for Q4 2025 on Monday, February 23rd. The company reported earnings of -$0.71 per share, missing estimates of -$0.68 by $0.03. The company also reported revenue of $196,000,000, missing estimates of $196,487,077 by $-487,077.
Stock price change since market open this morning: +2.25%
You can see Quiver Quantitative's $AXSM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AXSOME THERAPEUTICS Insider Trading Activity
AXSOME THERAPEUTICS insiders have traded $AXSM stock on the open market 32 times in the past 6 months. Of those trades, 3 have been purchases and 29 have been sales.
Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:
- HERRIOT TABUTEAU (Chief Executive Officer) has made 0 purchases and 16 sales selling 524,000 shares for an estimated $76,141,116.
- ROGER JEFFS has made 0 purchases and 5 sales selling 93,464 shares for an estimated $11,369,227.
- MARK E SAAD has made 0 purchases and 3 sales selling 46,704 shares for an estimated $7,348,482.
- MARK L. JACOBSON (Chief Operating Officer) has made 0 purchases and 3 sales selling 55,783 shares for an estimated $6,400,726.
- NICK PIZZIE (Chief Financial Officer) sold 12,000 shares for an estimated $2,255,040
- ARI MAIZEL (Chief Commercial Officer) sold 7,500 shares for an estimated $1,383,300
- MARK COLEMAN has made 3 purchases buying 1,575 shares for an estimated $200,466 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AXSOME THERAPEUTICS Hedge Fund Activity
We have seen 211 institutional investors add shares of AXSOME THERAPEUTICS stock to their portfolio, and 194 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACQUARIE GROUP LTD removed 1,084,536 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $198,079,655
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 815,176 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $148,883,744
- RTW INVESTMENTS, LP removed 628,902 shares (-41.5%) from their portfolio in Q4 2025, for an estimated $114,862,661
- PRICE T ROWE ASSOCIATES INC /MD/ added 472,422 shares (+45.5%) to their portfolio in Q4 2025, for an estimated $86,283,154
- BVF INC/IL removed 441,000 shares (-90.6%) from their portfolio in Q4 2025, for an estimated $80,544,240
- ROCKEFELLER CAPITAL MANAGEMENT L.P. added 412,404 shares (+7188.5%) to their portfolio in Q4 2025, for an estimated $75,321,466
- SOFINNOVA INVESTMENTS, INC. removed 381,233 shares (-96.9%) from their portfolio in Q4 2025, for an estimated $69,628,395
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AXSOME THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $AXSM in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 01/28/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/20/2026
- UBS issued a "Buy" rating on 01/06/2026
- Needham issued a "Buy" rating on 12/31/2025
- Mizuho issued a "Outperform" rating on 11/06/2025
- Morgan Stanley issued a "Overweight" rating on 11/04/2025
- RBC Capital issued a "Outperform" rating on 11/04/2025
To track analyst ratings and price targets for AXSOME THERAPEUTICS, check out Quiver Quantitative's $AXSM forecast page.
AXSOME THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $AXSM recently. We have seen 12 analysts offer price targets for $AXSM in the last 6 months, with a median target of $212.0.
Here are some recent targets:
- Ami Fadia from Needham set a target price of $225.0 on 02/23/2026
- Andrew Tsai from Jefferies set a target price of $245.0 on 02/03/2026
- Marc Goodman from Leerink Partners set a target price of $205.0 on 01/28/2026
- Leonid Timashev from RBC Capital set a target price of $219.0 on 01/21/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $260.0 on 01/20/2026
- David Amsellem from Piper Sandler set a target price of $223.0 on 01/16/2026
- Benjamin Burnett from Wells Fargo set a target price of $193.0 on 01/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
